IT IS NOW GENERALLY ACKNOWLEDGED that the subcellular location of signaling molecules generates specialized signal transduction compartments. Yet, this was not always an accepted concept. The German philosopher Arthur Schopenhauer wrote, truth passes through three stages: ridicule, violent opposition and then acceptance as being self-evident. Such was the case with signal transduction. During the early stages of its conceptual development, signal transduction in cells was thought to occur through a random process wherein signaling components randomly bumped into one another as if in a "bag" of molecules. It seemed impossible, even ridiculous, to think that stimuli interacted with molecules at discrete locations within cells. We now know that individual pathway components are organized into specific cellular microdomains such that diverse stimuli regulate complex systems of molecular interactions to orchestrate specialized spatial and temporal physiological outcomes. The importance of these concepts is becoming ever more evident as mechanisms of hormone and drug action are resolved to the subcellular location of their target molecules.
Activators of adenosine monophosphate-activated kinase (AMPK) are being investigated as treatments for type II diabetes mellitus and other diseases. The biguanide metformin and the thiazolidinediones, long known to improve blood glucose levels by increasing insulin sensitivity, act in part through AMPK (19) . More recently, the cardioprotective and antiangiogenic effects (among others) of the natural polyphenol resveratrol have been attributed to its actions on AMPK (14) . However, efficacy and safety questions remain, requiring additional studies before it can be introduced into clinical use (13) . A common theme is that benefits of these compounds attributed to AMPK occur as therapeutic "side effects," an observation that underscores the importance of defining drug interactions at the subcellular level.
The AMPK heterotrimer consists of an ␣-catalytic subunit and two regulatory and targeting subunits, ␤ and ␥. 5=-AMP activates AMPK by competing with ATP for binding to the ␥-subunit. During periods when ATP becomes depleted, AMP replaces ATP bound to the ␥-subunit. The AMP-bound ␥-subunit allosterically activates the serine-threonine kinase, switching on catabolic pathways that produce ATP, and switching off anabolic pathways that consume ATP. AMP-bound ␥ sensitizes the kinase to activation by upstream kinases that phosphorylate the ␣-catalytic subunit at Thr 172 (4) . Adenosine diphosphate (ADP), like AMP, binds ␥ and stimulates ␣-Thr 172 phosphorylation. In contrast to AMP, ADP does not directly activate AMPK. In this way, ADP-to-ATP and AMP-to-ATP ratios exert discrete contributions to AMPK regulation (1, 11) . Thus, AMPK integrates numerous regulatory signals important in monitoring energy status and maintaining cellular and organ homeostasis.
The three AMPK subunits possess unique structural components that contribute to differential roles in regulating AMPK location in cells. A nuclear localization sequence helps translocate the ␣ 2 -isoform between the cytoplasmic and nuclear compartments, while the ␣ 1 -isoform remains localizes to nonnuclear regions (9, 15) . In Drosophila, the ␣-subunit has a nuclear export sequence (7) . Shuttling of AMPK may also depend in part on the particular ␤-subunit isoform in the AMPK-␣/␤/␥ complex. The ␤-subunit serves as a scaffolding/ docking protein that binds ␣/␥ and appears to help determine the subcellular location of the AMPK complex (21) . In skeletal muscle, AMPK-␣ 2 /␤ 2 -containing complexes translocate from the cytosol to the nucleus in response to leptin activation, whereas AMPK-␣ 2 /␤ 1 complexes remain anchored in the cytosol (15) . The ␤ 1 -subunit is posttranslationally modified by myristoylation and phosphorylation (Ser 24, 25, 182 ) that attach the subunit and its ␣/␥-binding partners to a particulate extranuclear location (21) . In contrast, the ␤ 2 -subunit is distributed more homogeneously and does not localize to particulate cellular sites even though it contains the myristoylation and Ser 182 sites. The ␥ 1 -isoform also displays preferential nuclear localization compared with other isoforms. The molecular basis for this preference is not clear; however, it has been postulated that the 38-kDa subunit may passively enter the nucleus (18) .
Targets of AMPK phosphorylation include both cytoplasmic and nuclear proteins and it translocates between these subcellular compartments in a stimulus-dependent manner (8) . However, little is known about the dynamic nature of this distribution or whether experimental tools discriminate between the cytoplasmic and nuclear pools of AMPK. In this issue of American Journal of Physiology-Cell Physiology, Kodiha et al. (10) demonstrate the compartment-specific actions of three AMPK activators, phenformin, resveratrol, and 5-aminoimidizole-4-carboxamide riboside (AICAR). The authors assessed the effect of these agents on ␣-Thr 172 phosphorylation in the cytoplasm and nucleus to determine drug-induced changes in cell physiology. All three activators increased ␣-Thr 172 phosphorylation in the cytosol, whereas only AICAR significantly increased AMPK-␣ phosphorylation in the nucleus (Fig. 1A) . Acetyl-CoA-carboxylase 1 (ACC1), a predominantly cytoplasmic enzyme that is important in lipid metabolism, is a substrate of AMPK. The authors confirmed its phosphorylation by all three agents (Fig. 1B) in the cytosol. Consistent with the multifunctional roles of AMPK, its actions are also linked to mechanisms involved in cell cycle regulation and protein synthesis inhibition (20) . The authors assessed de novo RNA synthesis in nucleoli as a measure of AMPK activity associated with the nucleus and found that only resveratrol had significant action in this compartment (Fig. 1C) . Overall, this study demonstrates agent-dependent differences in AMPK phosphorylation within subcellular compartments. Moreover, these location-specific effects lead to differential regulation of essential cellular processes and provide important insights into the molecular basis of physiological outcomes associated with the use of activators of AMPK. This study also highlights an important question: What clinical promise do studies of AMPK hold for the future?
Hyperphosphorylation of tau is a hallmark of Alzheimer's disease, and although mechanisms underlying this pathological phosphorylation are not fully understood, impaired energy metabolism is thought to influence signaling events associated with its presence. AMPK phosphorylates tau in response to A␤ (amyloid-␤ peptide), a process inhibited by memantine, a partial antagonist of N-methyl-D-aspartate (NMDA) receptors, that is used in the treatment of Alzheimer's disease (16). Huntington's disease, another neurodegenerative disorder, has links to aberrant activation of AMPK-␣ 1 in the nuclei of striatal cells. In striatum, overactivation of AMPK causes brain atrophy, facilitates neuronal loss, and increases formation of huntingtin gene aggregates (6) . Nuclear accumulation of AMPK-␣ 1 is activity dependent; prevention of nuclear translocation of AMPK-␣ 1 ameliorates cell death (6) .
Therapeutic potential for AMPK is not limited to mechanisms associated with cytoplasmic and nuclear compartments. Plasma membrane lipid rafts (caveolae) are signaling microdomains. Caveolins in these cholesterol-and sphingolipid-enriched membranes help tether these microdomains to the cytoskeleton and via a unique scaffolding domain sequester receptors, ion channels, second messenger-producing enzymes, and effector kinases (5, 12) to these specialized membrane compartments. Caveolin signaling microdomains are important for regulating endothelial barrier integrity as recently described for AMPK-␣ 1 , which colocalizes in caveolar membranes in lung capillary endothelium with caveolin-1 and the cell adhesion molecule N-cadherin, and contributes to vascular repair mechanisms (2) .
A current limitation in the study of AMPK is an inability to resolve its activity to more discrete locations within the cell. A biosensor, AMPKAR, which exhibits enhanced Förster resonance energy transfer (FRET) in response to phosphorylation by AMPK, holds such promise. This tool responds to AMPK-␣ 1 -and ␣2-dependent stimuli that induce energy stress and allows spatiotemporal monitoring of AMPK activity in single cells (17) . Although observation of AMPK activation has been confined to studies involving the cytosol and nucleus, manipulation of this FRET probe could target it to specific subcellular locations (3). FRET probes have been covalently linked to molecules that target specific subcellular regions, including lipid rafts. Modification of such tools to assess AMPK should prove valuable in identifying discrete pools of AMPK activity and resolving their differential regulation by stimuli.
With the advances in understanding gained from studies such as the current article by Kodiha et al., the wide-ranging roles of AMPK in physiological processes will continue to make it of interest to cell physiologists and an attractive target for drug discovery.
